SCHEMBL4464967

SCHEMBL4464967

COc1c(C(C)(C)C)cc(C(=N)N)cc1C(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNFRSF1A P19438 2/20 0.44
PRSS1 P07477 6/20 0.42
PRSS2 P07478 3/20 0.42
PRSS3 P35030 3/20 0.42
C1S P09871 1/20 0.42
PTGS2 P35354 3/20 0.40
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
DHFR P00374 1/20 0.37
PTGS1 P23219 1/20 0.36
F10 P00742 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
KLK1 P06870 1/20 0.36
PTGIR P43119 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3579165 0.81 TNFRSF1A (0.51) TNFRSF1APTGS2CA1CA2DHFR
SCHEMBL3587740 0.81 TNFRSF1A (0.44) TNFRSF1APTGS2CA1CA2DHFR
SCHEMBL3637333 0.74 TNFRSF1A (0.56) TNFRSF1APTGS2CA1CA2
SCHEMBL2772941 0.74 TNFRSF1A (0.53) TNFRSF1APTGS2CA1CA2PTGS1
SCHEMBL3370885 0.74 CYP3A4 (0.52) PRSS1PRSS2PRSS3C1SCYP3A4
SCHEMBL5677096 0.73 TNFRSF1A (0.51) TNFRSF1APTGS2CA1CA2LMNA
SCHEMBL3157771 0.73 TDP1 (0.52) TNFRSF1APTGS2CA1CA2DHFR
SCHEMBL29113869 0.73 PTGS2 (0.46) TNFRSF1APTGS2CA1CA2DHFR
SCHEMBL8608299 0.71 TNFRSF1A (0.46) TNFRSF1ATP53HPGDALDH1A1
SCHEMBL27871656 0.70 TNFRSF1A (0.49) TNFRSF1APTGS2PTGS1LMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
WO-2007100610-A2 PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS MERCK & CO., INC. (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030012-A1 Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators CXCR3, CXCR1, CXCR5 TNFRSF1A 286/4885PRSS1 2596/4885PRSS2 4215/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.